ModMed to Showcase the Latest Advancements in Its Dermatology ... Business Wire
Originally posted here:
ModMed to Showcase the Latest Advancements in Its Dermatology ... - Business Wire
Category Archives: Dermatology
Associates in Dermatology responds to data breach | News … – Evening News and Tribune
NEW ALBANY Associates in Dermatology (AID), a health-care provider with offices in New Albany and Clarksville, is notifying community members of a data breach issue.
On Monday, the provider announced in a news release that Virtual Private Network (VPN) Solutions faced a ransomware issue that could potentially affect patients of the dermatology clinic. The company provides electronic health record management software for the provider.
The New Albany office is at 2241 Green Valley Road, and the Clarksville office is at 1005 E Lewis and Clark Parkway.
The data breach took place around Oct. 31, 2021, leading to a forensic investigation. The investigation did not conclude until January of this year. VPN identified files pertaining to AID that potentially contained sensitive information.
On March 10, 2023, AID determined that the compromised files may have also contained personally identifiable information, the news release said. AID is working to identify all the specific individuals and the type of data that was impacted by VPNs breach in order to provide sufficient notice. AID has no reason to believe that any individuals information has been misused as a result of this event.
The news release said that compromised data may include patients names, addresses, Social Security numbers, dates of birth, medical conditions, treatments, diagnoses, test results, health insurance policy numbers, subscriber identification numbers and health plan beneficiary numbers. The data that VPN identified as compromised varied with each individual.
Al Appel, chief administrative officer for AID, said the company is notifying affected individuals as a matter of precaution.
As far as we understand, there was not any [protected health information] that was accessed by the hackers, he said.
AID is offering free credit monitoring and identity theft protection to patients potentially affected by the data breach. The provider is sending out letters to notify patients of the data breach and the available services.
Those seeking additional information can call AIDs helpline at 1-833-570-2973 between 8 a.m. and 8 p.m. Central Time Monday through Friday.
VPN has also taken steps to secure data, including adding robust security controls and endpoint detection/response solutions, according to the news release.
Dr. Al Knable, a dermatologist at AIDs New Albany location, encourages patients to sign up for the free credit monitoring services.
We have 11 locations and cumulatively throughout Kentuckiana, were seeing probably close to 1,500 patients a day, he said. Its a huge responsibility that we dont take lightly, which is why weve always exceeded the minimum standards. And with what were doing now, were exceeding those standards.
More here:
Associates in Dermatology responds to data breach | News ... - Evening News and Tribune
AMERICAN ACADEMY OF DERMATOLOGY: RESEARCH SUGGESTS CONNECTION BETWEEN HAIR LOSS IN WOMEN AND OTHER DISEASES – Yahoo Finance
Board-certified dermatologist discusses common types of hair loss seen in women with darker skin tones
NEW ORLEANS, March 17, 2023 /PRNewswire/ -- Hair loss in women can be emotionally devastating and may negatively impact quality of life, and new research suggests that it can also be associated with having other common medical conditions. A board-certified dermatologist at the American Academy of Dermatology's Annual Meeting in New Orleans will discuss the types of hair loss seen in women with darker skin tones, common types of medical conditions associated with hair loss, and hair loss treatment options.
"Research shows that women who experience hair loss can also have other medical conditions like diabetes, acne, and breast cancer," said board-certified dermatologist Valerie D. Callender, MD, FAAD, professor of dermatology at Howard University College of Medicine. "By recognizing the signs of hair loss and seeing your dermatologist as soon as possible, you may be able to limit the progression, hold on to the hair you have, and discover any other underlying medical conditions you may have."
Central centrifugal cicatricial alopecia (CCCA), which causes hair loss in the center, or crown, of the scalp, is the most common type of hair loss seen in women with darker skin tones. It is estimated to affect nearly 15% of Black women1, says Dr. Callender.
Early detection is important to preserve and protect your hair because CCCA can cause scarring by destroying hair folliclesthe tiny openings from which your hair grows. While it's possible to regrow some hair, once the hair follicle scars completely, regrowing hair becomes difficult and hair loss can be permanent.
A board-certified dermatologist can diagnose the type of hair loss you have and work with you to determine the best course of treatment for CCCA, which can include antibiotics, topical steroid medication, or corticosteroid injections. These medications may give patients relief from the pain, tenderness, and itching they're feeling in an affected area, as well as prevent scarring from getting worse.
Story continues
Conditions such as breast cancer, high cholesterol, diabetes, and high blood pressure2-3 are common among Black women with CCCA, says Dr. Callender. If you have CCCA, your dermatologist may be able to tell you if the other symptoms you're experiencing are caused by a dermatologic condition, or if they are a symptom of another disease.
Another common type of hair loss is female pattern hair loss, which affects millions of women of all skin tones. In female pattern hair loss, the hair thins mainly on the top of the scalp, and it usually starts with a widening of the center hair part. This type of hair loss is hereditary, and many women who have female pattern hair loss also have acne4 due to an increase in hormones, says Dr. Callender. While acne is more common in the early stages of female pattern hair loss, menopause and high blood pressure are common as female pattern hair loss progresses.
Minoxidil is a common treatment option for female pattern hair loss because it has been shown to reduce hair loss, stimulate hair growth, and strengthen existing strands of hair. Although minoxidil can be found in products at the drugstore, it's important to consult with a board-certified dermatologist as your hair loss may need to be treated with a higher dosage that is only available with a prescription. Your dermatologist can also advise you on how to apply the treatment to your scalp.
While braids, a ponytail, or an updo can look great, Dr. Callender says hairstyles that tightly pull the hair can cause traction alopecia, which is a common type of hair loss in women with darker skin tones due to hair styling.
"One of the first things I ask my patients who have a history of braids is if it hurts when their hair is braided," said Dr. Callender. "Getting your hair done shouldn't hurt, so if they have pain, it's an indicator that they could be developing traction alopecia."
Fortunately, there are options that allow a person to keep their sense of style without losing their hair. Loosening up the hairstyle, avoiding frequently wearing hairstyles that pull on your hair, and changing hairstyles can all help prevent traction alopecia.
It is especially important for women with any type of hair loss to consider the ingredients in their products. Women with darker skin tones, particularly those of African descent, have hair that tends to be coarse, dry, and fragile, says Dr. Callender. Some of the shampoos for dandruff and other scalp disorders can further dry out hair, leading to breakage. Patients with darker skin tones should use shampoos and hair products with ingredients that moisturize their hair such as vitamins A and E, jojoba oil, and shea butter.
"When treatments are not effective to prevent hair loss, a permanent solution is to consider a hair transplant, which creates natural-looking results," said Dr. Callender. "Hair transplants are most effective in patients with traction alopecia and female pattern hair loss. While patients with CCCA aren't always ideal candidates for a hair transplant due to scarring, it is possible for them to have success. A board-certified dermatologist can determine if a hair transplant is the right option."
Board-certified dermatologists are the experts in the diagnosis and treatment of hair loss. To find a board-certified dermatologist in your area, visit aad.org/findaderm.
More InformationHair loss resource centerCentral centrifugal cicatricial alopeciaFemale pattern hair lossTraction alopecia
About the AADHeadquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 20,800 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, Pinterest and YouTube and @AADskin1 on Instagram.
Editor's note: The AAD does not promote or endorse any products or services. This content is intended as editorial content and should not be embedded with any paid, sponsored or advertorial content as it could be perceived as an AAD endorsement.
1Aguh, Crystal and Amy McMichael. "Central Centrifugal Cicatricial Alopecia." JAMA Dermatology, vol. 156, no. 9, 1 Sept. 2020, p. 1036, https://doi.org/10.1001/jamadermatol.2020.1859.2 Comorbidities in patients with central centrifugal cicatricial alopecia: A retrospective chart review of 53 patients Leung, Bonnie et al. Journal of the American Academy of Dermatology, Volume 88, Issue 2, 461 4633Association of breast and colorectal cancer in patients with central centrifugal cicatricial alopecia: A cross-sectional, pilot study Brown-Korsah, JessicaRoche, Fritzlaine C.Taylor, Susan C. et al. Journal of the American Academy of Dermatology, Volume 85, Issue 3, AB744The comparison of demographics and comorbidities of female pattern hair loss according to the clinical subtype and stage zkoca, Defne et al. Journal of the American Academy of Dermatology, Volume 87, Issue 4, 779 - 783
Cision
View original content:https://www.prnewswire.com/news-releases/american-academy-of-dermatology-research-suggests-connection-between-hair-loss-in-women-and-other-diseases-301775039.html
SOURCE American Academy of Dermatology
See the original post here:
Aldena Therapeutics Accelerates its Novel and Disruptive Approach to Immuno-Dermatology – Yahoo Finance
Founded by MedicxiwithGeorgia Tech and UMass scientists, supported byUS $30M investment from Medicxi
Developing advanced, long-lasting therapies for dermatological diseases through radical new transepidermal delivery of proprietary siRNAs
Led by dermatology veteran Thibaud Portal as CEOwith a Scientific Advisory Board chaired by Nobel Prize Laureate, Craig Mello
BOSTON, March 16, 2023 /PRNewswire/ -- Aldena Therapeutics Inc. (Aldena) a private biotech company pioneering siRNA-based therapies for dermatological indications, announces an update on its innovative, immuno-dermatology pipeline, appointment of world leading Scientific Advisory Board (SAB) and US$ 30 million financing by Medicxi.
Under the leadership of CEO, dermatology industry veteran Thibaud Portal, Aldena's goal is to develop advanced, long-lasting treatments for dermatological diseases based on its disruptive approach to immuno-dermatology. The company's technology has the potential to capture the full value of systemically validated Mode of Actions (MOA) through radical new transepidermal delivery of proprietary siRNAs.
Aldena was co-founded by Professor John Harris (MD, PhD, Professor and Chair of Dermatology at UMass Chan Medical School), Professor Mark Prausnitz (PhD, Regents' Professor at Georgia Institute of Technology) and Dr Andrew Tadros (MD, PhD) and backed by Medicxi.
Craig Mello, PhD, the Physiology and Medicine Nobel Prize Laureate will Chair the SAB, alongside specialists in the field of dermatology; Lars French, MD, PhD, Jonathan Silverberg, MD, PhD, MPH and Anastasia Khvorova, PhD, who will join founding advisors John Harris, MD, PhD and Mark Prausnitz, PhD on the SAB as core experts to serve as its strategic resource to establish Aldena's efforts to expand its innovative, pipeline of Dermatology products.
Aldena has a pipelineof six different compounds, three of which will be ready forIND filing next year. Theinnovative pipeline of dermatological siRNA therapies are targeting the unmet medical need in conditions like Atopic Dermatitis, Vitiligo, Alopecia Areata, Psoriasis and other inflammatory diseases.
Story continues
Thibaud Portal, Chief Executive Officer of Aldena Therapeutics, said:"I am delighted to reveal Aldena Therapeutics as we accelerate our mission to develop an innovative pipeline of dermatological siRNA therapies that have the potential to transform the treatment of multiple dermatological diseases. I am honored to have such world leaders in the scientific and medical fields on our scientific advisory board which is significant validation of our approach. Their deep and diverse expertise across the fields of siRNA research and development, of advanced drug delivery solutions and of development of groundbreaking dermatologic products, will be immensely valuable as we continue to advance our pipeline."
Craig Mello, Chair of Aldena Therapeutics Scientific Advisory Board, commented: "The most influential way to make a lasting impact in the life science community is to create pioneering, effective products that address the unmet medical need of patients. I am delighted to chair this multidisciplinary and highly experienced Scientific Advisory Board, where engineers, scientists, and medical professionals come together to develop innovative, dermatological products for the benefit of millions of patients."
Francesco De Rubertis, co-founder and Partner at Medicxi, member of the Board of Directors of Aldena, added: "We are delighted to collaborate with leading scientists from Georgia Tech and UMass to create Aldena Therapeutics, a company based on its truly disruptive approach to immuno-dermatology. Aldena brings together a phenomenal team of leaders with expert knowledge to develop transformative and long-lasting therapies for many dermatology diseases."
Scientific Advisory Board
Prof. Craig C. Mello:is an Investigator at the Howard Hughes Medical Institute, the Blais University Chair in Molecular Medicine, and co-director of the RNA Therapeutics Institute at the University of Massachusetts Chan Medical School (UMCMS). His research is aimed at deciphering the molecular mechanisms underlying small-RNA-silencing in C Elegans to inform the understanding of human health and disease. Prof. Mello was a co-recipient, with Andrew Z. Fire, of the Nobel Prize for Physiology and Medicine in 2006 for discovering RNA interference (RNAi), a mechanism that regulates gene activity. In addition, Prof. Mello received the 2003 Wiley Prize, the 2003 National Academy of Sciences Award in Molecular Biology, the 2004 Warren Triennial Prize, the 2005 Canada Gairdner International Award, the 2005 Massry Prize and was also awarded the title of Howard Hughes Medical Investigator for his significant contributions to science.
Dr. Med. Lars E French:is a professor and chairman of the Department of Dermatology at the Munich University of Ludwig Maximilian (LMU) in Germany. Professor French is a clinician and a scientist engaged in competitive research and development in the field of inflammatory skin disease and tumour immunology. In 2012, Professor French was awarded the Otto Naegeli Prize for the promotion of medical research, one of Switzerland's most prestigious scientific awards.
Dr. Jonathan Silverberg:is an Associate Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC. He is the Director of Clinical Research and Contact Dermatitis. Dr. Silverberg's area of clinical subspecialty is inflammatory skin diseases, and research interests include drug development, clinical trial design, biomarkers, dermato-epidemiology, health services research, patient-reported outcomes, comorbidities and burden of itch and inflammatory skin disease and evidence-based dermatology. He has been recognized with several honours, including the Young Leadership Award from the American Dermatological Association in 2017, Teacher of the Year Award in the department of dermatology in 2015, Outstanding Teacher's Award from the Feinberg School of Medicine in 2016, 2017 and 2018, and the inaugural Rajka Award from the International Society for Atopic Dermatitis in 2014.
Dr. Anastasia Khvorova:has more than 20 years of experience developing oligonucleotide technology and therapeutics. She is a professor in the RNA Therapeutics Institute and Program of Molecular Medicine at the University of Massachusetts Chan Medical School (UMCMS), where her lab develops novel approaches and solutions to understanding natural and therapeutic RNA trafficking and delivery. Dr. Khvorova founded the UMass Nucleic Acid Chemistry Core after several years in industry, during which she served as Chief Scientific Officer (CSO) at leading biotech companies and co-founded several start-ups.
Scientists and academic collaborators of Aldena will be presenting at the upcoming Dermatology Innovation Forum in New Orleans on March 16th 2023, and at the first International Societies for Investigative Dermatology Meeting in Tokyo, 1-13 May 2023.
About AldenaAldena Therapeutics is a Boston, Lausanne and London-based biotechnology company focusing on siRNA-based treatments for patients suffering from dermatological diseases. The Company was co-founded by Prof. John Harris (MD, PhD, Professor and Chair of Dermatology at UMass Chan Medical School), Prof. Mark Prausnitz (PhD, Regents' Professor at Georgia Institute of Technology) and Dr Andrew Tadros (MD, PhD) and is backed by international investment firm, Medicxi. Aldena Therapeutics has been led since its inception by dermatology specialist, CEO, Thibaud Portal, PhD, who previously led the Prescription Medicines business and strategy of Galderma SA after several senior R&D roles and co-founded several dermatology focused start-up companies. Aldena is pursuing multiple innovative programs and is currently initiating the IND-enabling GLP nonclinical program for its lead projects.
About MedicxiMedicxi is a healthcare-focused investment firm with the mission to create and invest in companies across the full drug development continuum. Leveraging deep expertise in drug development and company creation spanning over two decades, Medicxi invests in early and late-stage therapeutics with a product vision that can fulfill a clear unmet medical need. For more information, please visit: https://www.medicxi.com
Cision
View original content:https://www.prnewswire.com/news-releases/aldena-therapeutics-accelerates-its-novel-and-disruptive-approach-to-immuno-dermatology-301773160.html
SOURCE Aldena Therapeutics
See the rest here:
Treating Body Dysmorphic Disorder in Cosmetic Patients – Dermatology Times
Body Dysmorphic Disorder (BDD) is a psychiatric diagnosis, however, the prevalence of patients that suffer from BDD is higher among dermatology patients, than in the background population.1 In his session at the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans, Louisiana, Geoge Kroumpouzos, MD, PhD, FAAD, explored the relationship between psychocutaneous disease patients and the role their dermatologist or cosmetic surgeon may play in diagnosing and treating the disease.
Krompouzos is director of GK Dermatology, clinical associate professor of dermatology at Brown University, and Board Member of the International Academy of Cosmetic Dermatology. In his session, "Psychocutaneous Disease: Treating the Difficult Patient", Kroumpouzos focused on managing such conditions in the complex patient and how to approach a patient with BDD in the dermatology space.
Transcript
George Kroumpouzos, MD: I'm George Kroumpouzos, I am a dermatologist in Massachusetts. I'm in solo practice and I'm also teaching at Brown University as a clinical associate professor, and I have combined both clinical and cosmetic dermatology. Psychodermatology is one of the fields on which a focus in my practice.
Dermatology Times: How common is BDD in dermatology patients?
Kroumpouzos: Psychiatric comorbidity is very common in my practice, but it's common also in dermatology. In general, the prevalence of body dysmorphic disorder (BDD )in dermatology is 8.5 to 15%, but likely higher in cosmetic surgery patients. In that group, the prevalence ranges between 6 and 20% in various statuses. So very status encounter a psychiatric condition in 1 out of 3 dermatology patients. We see patients with psychiatric comorbidity all the time.
Dermatology Times: How common is BDD in dermatology patients?
Kroumpouzos: Well, distress and functional impairment are common denominators among BDD patients and patients with other psychiatric issues. Emotional distress is often quite apparent during a brief interview. Dermatologists should try to evaluate psychosocial issues and the patient's quality of life. It's important to know how much the problem affects the quality of life of the patient. Lack of insight correlates with the severity of the pyscho dermatologic conditions. So patients who have a lack of insight or complete lack of insight are always difficult to manage. And I would always encourage other dermatologists to look into the patient's quality of life and try to elucidate other psychosocial issues.
Dermatology Times: What signs should a dermatologist or cosmetic surgeon look for to diagnose BDD in patients?
Kroumpouzos: There are 3 elements in the diagnosis process. Warning signs, which we also call red flags, from the history and in-office observation; a structured interview that doesn't need to be long, and a BDD questionnaire. Not every practice uses a disability questionnaire, but there are BDD questionnaires that are only 7 questions long, and they're easy to fill out in 5 minutes so the patient would not mind taking that questionnaire. Now the red flags from the history interview include a belief of the patient that surgery will solve all problems based on its design and dissatisfaction with the outcomes of previous procedures; they're never happy. And there is often a history of comorbidity or psych comorbidity or pysch treatment. And if we look carefully at the patient's records, we'll find that previous psych treatment. Now red flags from the novice observation include repeated consultations for the perceived defect. So the patient goes from physician to physician, from aesthetic provider to aesthetic provider, to ask their opinion about the same defect. These patients bring photographs [social media images of celebrities], they ask the nurses to compare them with a celebrity, and they often reveal their preoccupation to the staff. So this patient often refused to undergo standard preoperative evaluations, which is another red flag. So if we see a patient with all these warning signs, we should suspect BDD and again, the best way to confirm it is to provide final a questionnaire to the patient. Some of these questionnaires do not take more than 5 minutes to complete.
This transcript has been edited for clarity and length.
Reference
1. Herbst, I., Jemec, G.B.E. Body Dysmorphic Disorder in Dermatology: a Systematic Review. Psychiatr Q91, 10031010 (2020). https://doi.org/10.1007/s11126-020-09757-y
See original here:
Treating Body Dysmorphic Disorder in Cosmetic Patients - Dermatology Times
More Vitiligo Patients Respond with Longer Use of Opzelura – Managed Healthcare Executive
Longer-term use of Opzelura was well tolerated, with no serious treatment-related adverse events, according to a poster presented at the annual dermatology meeting.
Patients with vitiligo treated with Incytes Opzelura (ruxolitinib) largely improved or remained stable in their responses through week 52, according to a pooled analysis of two phase 3 studies. The results were presented during a poster presentation at the annual meeting of the American Academy of Dermatology Association in New Orleans, March 17 to March 20, 2023.
Vitiligo is a disease that causes the loss of skin color. Vitiligo occurs when cells that produce melanin die or stop functioning. Vitiligo affects people of all skin types, but it may be more noticeable in people with darker skin. The exact cause is unknown, but it is believed to be an autoimmune condition.
Worldwide prevalence estimates of vitiligo vary widely, ranging from 0.004% to 2.28%. One study suggests that about 40% of patients with vitiligo may be undiagnosed.
Incytes Opzelura is the first FDA-approved treatment for this condition and is the only topical formulation of a Janus kinase (JAK) inhibitor approved in the United States. The approved approved it for this indication in June 2022. For patients over the age of 12. Over-activity of the JAK signaling pathway is believed to drive inflammation involved in vitiligo.
The approval was based on data from the pivotal phase 3 TRuE-V clinical trial program (TRuE-V1 and TRuE-V2), evaluating the safety and efficacy of Opzelura versus vehicle in people with vitiligo at week 24. In the studies, treatment with Opzelura resulted in improvements in Vitiligo Area Severity Index (VASI) scores, which represent improvements in facial and total body repigmentation. At week 24, about 30% of patients treated with Opzelura achieved 75% or more improvement in the facial VASI, the primary endpoint, compared with a non-medicated cream in 8% of patients in the TRuE-V1 study and 13% of patients in the TRuE-V2 study.
Investigators, led by John E. Harris, M.D., Ph.D., associate professor in the department of Dermatology at the University of Massachusetts Chan Medical School, wanted to evaluate the changes in improvement or stability of facial vitiligo among patients who used Opzelura for 52 weeks.
At week 24, about 30% of patients treated with Opzelura achieved 75% or more improvement in the facial VASI, the primary endpoint, compared with a non-medicated cream in 8% of patients in the TRuE-V1 study and 13% of patients in the TRuE-V2 study. At week 52, about 50% of Opzelura-treated patients achieved 75% or more improvement. Additionally, at week 24, more than 15% of patients treated with Opzelura achieved 90% or more improvement in the facial VASI. At week 52, about 30% of Opzelura-treated patients achieved this improvement.
Opzelura was well-tolerated through 52 weeks of treatment. A total of 58.6% of patients experienced 1 treatment-emergent adverse event (AE), most commonly COVID-19 (7.3%), application site acne (6.5%), nasopharyngitis (5.8%), and application site pruritus (5.3%). Application site reactions were the most common treatment-related adverse events; these included acne (5.6%) and pruritus (4.7%), all of which were mild or moderate. No serious adverse events were considered related to treatment. There were no clinically significant changes in hemoglobin or platelet levels.
The study was funded by Incyte.
More here:
More Vitiligo Patients Respond with Longer Use of Opzelura - Managed Healthcare Executive
CeraVe Puts Dermatologists on Parade in New Orleans to Reinforce … – PR Newswire
All sun exposure, even indirect or unintentional, can still impact the skin. In fact, according to the International Ultraviolet Association, normal glass (as used in windows) is transparent to UV radiation, so almost all UVA light will pass through glass.3 Yet, a recent CeraVe survey of Americans4 showed that sitting near windows is one of the moments where they are least likely to apply sunscreen, with 29% citing when working indoors by a window and 28% while driving two different behaviors that expose skin to UV rays. The same survey found that 23% say they are least likely to apply sunscreen when it is cloudy, and a whopping 64% even admitted they don't think they need to wear sunscreen every day. However, like brushing teeth, it's critical to apply daily for optimal skin health.
"Wearing sunscreen every day is one of the easiest, yet most important ways to keep skin healthy, but it is often overlooked as a regular step in a skincare routine, particularly when it is not a hot, sunny day," said board-certified dermatologist Dr. Nkem Ugonabo, M.D., M.P.H. "Regardless of the season, weather, location or activities, applying SPF daily is essential to help protect skin from UV exposure which will have both short- and long-term benefits for the skin. This can be as simple as incorporating CeraVe's moisturizer with broad-spectrum SPF 30 into a skincare routine each morning."
A clinical L'Oral study released in the Journal of Drugs in Dermatology5found that daily sun exposure not only damages skin cells, but also significantly reduces the level of ceramide 3 in the skin and impairs the quality of essential ceramides 1, 3 and 6-II in the skin barrier. Ceramides, which are lipids found in the skin barrier, are a critical component of skin barrier protection, making CeraVe AM Facial Moisturizing Lotion a key to a healthy morning skincare routine. Enriched with these essential ceramides and hyaluronic acid for hydration, this broad-spectrum sunscreen helps protect from short-term and long-term damage caused by exposure to UV rays, while simultaneously hydrating and restoring the skin barrier.
"As part of our commitment to providing therapeutic skincare for all, CeraVe is making dermatological advice more accessible and digestible so that everyone has the tools they need for achieving healthy skin," said Gene Coln, Global Senior Vice President, Medical Relations & Communications for CeraVe at L'Oral. "Dermatologists are both our biggest advocates and the most trusted resources for consumers, so by pairing them with some of the internet's most popular names, we are expanding our reach of critical sun care education and ultimately, helping people improve their daily skincare habits for healthier skin."
CeraVe goes beyond traditional marketing to educate consumers on skin health. Extensive information about the science of skin, skin types and common skin concerns is easily accessible through the brand's website and social pages. Plus, authentic collaborations with dermatologists and other healthcare professionals further help drive and empower consumers to make the best decisions for their skin. From quizzes and self-assessments to a range of resources and products all to help consumers understand their skin and choose the right products for their specific needs.
CeraVe AM Facial Moisturizing Lotion with SPF 30 is one of the many products in the full range of dermatologist-developed therapeutic skincare products with three essential ceramides, including cleansers and body moisturizers. For more skincare tips and product information, visit CeraVe at http://www.cerave.com and on Facebook, Instagram, TikTok and Twitter.
1IQVIA, ProVoice Survey, 12 months ending November 20222The American Academy of Dermatology Sunscreen FAQ: https://www.aad.org/media/stats-sunscreen3International Ultraviolet Association:https://iuva.org/UV-FAQs/4This survey was conducted online within the United States by OnePoll on behalf of CeraVe from April 16, 2020 April 21, 2020 among 2,000 U.S. adults ages 18 and older.5Barresi, Rebecca, et al. "Alteration to the Skin Ceramide Profile Following Broad-Spectrum UV Exposure." Journal of drugs in dermatology: JDD 21.1 (2022): 77-85.
About CeraVe
Founded in 2005 and developed with dermatologists, CeraVe is the first and only brand to offer a complete line of products containing essential ceramides and MVE technology to help restore the skin's natural protective barrier. CeraVe has a full line of skincare products to follow the dermatologist-recommended steps of: cleanse, treat, moisturize, and protect. The brand's mission is to provide therapeutic skincare for all. For more information, visit the brand on Facebook, Instagram or Twitter or at http://www.cerave.com.
SOURCE CeraVe
More here:
CeraVe Puts Dermatologists on Parade in New Orleans to Reinforce ... - PR Newswire
FDA Approves Retifanlimab-Dlwr for the Treatment of Metastatic or … – Dermatology Times
The US Food and Drug Administration (FDA) has approved Incyte Corporations retifanlimab-dlwr (Zynyz) for the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in adults.1 The FDA approved Incytes Biologics License Application for MCC treatment with retifanlimab-dlwr, a humanized monoclonal antibody targeting programmed death receptor-1,under accelerated approval based on tumor response rate and duration of response (DOR). According to Incyte, continued approval of retifanlimab-dlwr for MCC may be contingent on verification and description of clinical benefit in confirmatory trials.
The FDAs approval of retifanlimab-dlwr is based on data from Incytes POD1UM-201 clinical trial (NCT03599713), an open-label, multiregional, single-arm study that evaluatedretifanlimab-dlwrin adults with metastatic or recurrent locally advanced MCC who had not received prior systemic therapy. Out of patients who had never received chemotherapy (n=65), retifanlimab-dlwr as monotherapy demonstrated an objective response rate (ORR) of 52% (95% confidence interval: 40-65) determined by independent central reviewusing RECIST v1.1.
"For those of us who have significant cutaneous oncology practices, the treatment of MCC has always been a challenge. Although we have treated this serious skin cancer with Mohs surgery for decades, local recurrences and metastases have always been a challenge. Incytes long-awaited FDA clearance of Zynyz for metastatic or recurrent locally advanced MCC provides our patients a long-needed adjunctive treatment approach," said David J. Goldberg, MD, JD, medical director of Skin Laser and Surgery Specialists of New York and New Jersey; director of cosmetic dermatology and clinical research at Schweiger Dermatology Group in New York, New York; and clinical professor of dermatology and past director of Mohs Surgery and Laser Research at the Icahn School of Medicine at Mount Sinai in New York, New York.
Complete response was observedin 12 patients (18%), and 22 patients (34%) showed partial response. Among the responding patients, the DOR ranged from 1.1 to 24.9+ months,76% (26/34) experienced a DOR of 6months or longer, and 62% (21/34) experienced a DOR of 12 months or longer by landmark analysis.
Some serious adverse events (AE) were observed in 22% of patients who received retifanlimab-dlwr. The most frequent serious AEs ( 2% of patients) were fatigue, arrhythmia, and pneumonitis. Due to AEs, 11% of patients discontinued retifanlimab-dlwr. The most common AEs (10%) observed in patients were fatigue, musculoskeletal pain, pruritus, diarrhea, rash, pyrexia, and nausea.
Patients receivedretifanlimab-dlwr 500 mg intravenously every 4 weeks until disease progression, unacceptable toxicity, for up to 24 months. Tumor response assessments were performed every 8 weeks for the first year of therapy and 12 weeks afterward.
The primary endpoint of POD1UM-201 was ORR determined by an independent central radiographic review using RECIST v1.1. Secondary endpoints included DOR, disease control rate, progression-free survival, and overall survival, as well as observed safety and pharmacokinetics.
Retifanlimab is also being studied in other POD1UM clinical trials for the treatment of squamous cell carcinoma of the anal canal.
Reference
Read more:
FDA Approves Retifanlimab-Dlwr for the Treatment of Metastatic or ... - Dermatology Times
Cancer Treatment’s Checkpoint Inhibitors Are Causing Skin-Related … – Managed Healthcare Executive
Checkpoint inhibitors, such as Keytruda (pembrolizumab) and Opdivo (nivolumab), are playing a major role in cancer treatment. But they also produce side effects that affect the skin. Steven Chen, M.D., M.P.H., M.H.P. Ed., said dermatologists need to work with oncologists to manage the side effects so patients can stay on checkpoint inhibitors.
Immunotherapies, specifically immune checkpoint inhibitors, have provided patients with a life-saving option for many cancers. Checkpoint proteins are part of the normal immune system, and they work to keep the immune response measured and controlled. But checkpoint proteins also steer the immune system away from attacking cancer. Drugs that block checkpoint proteins unleash the immune system's T cells so they identify and kill cancer cells.
Several different types of checkpoint inhibitor drugs are now being used to treat many types of tumors and blood cancers, including Keytruda (pembrolizumab), Opdivo (nivolumab) and Tecentriq (atezolizumab). But toxicity from these therapies can affect almost every organ system. Skin conditions, such as dermatitis, psoriasis, eczema, pruritus (itchy skin), are one of the most common adverse events related to checkpoint inhibitors.
Skin-related adverse events are likely to increase as the number of FDA- approved checkpoint inhibitors increase and as various combinations get used, Steven T. Chen, M.D., M.P.H., M.H.P. Ed., vice chief of education in the Department of Dermatology at Massachusetts General Hospital in Boston, said today at a presentation at the annual meeting of the American Academy of Dermatology.
Since the approval of the first checkpoint inhibitor Yervoy (ipilimumab) in 2011 to treat patients with advanced melanoma approvals have steadily increased. New combinations especially for solid tumor and next-generation checkpoint inhibitors are in development.
But there is also likely to be variability in patient response to the various therapies and the type of reactions patients have, said Chen. In fact, of the patients with melanoma who are treated with Yervoy, 44% had a dermatological adverse event whereas only 12% of patients with non-small cell lung cancer patients who are treated with Keytruda had dermatological adverse event.
Toxicities most often occur in the first three months of treatment with checkpoint inhibitors, but can arise at any time during or even several months after treatment stops. Some patients experience rashes after just one dose of a checkpoint inhibitor. For other patients, the adverse event could occur after treatment stops. Patients can also experience more severe forms of skin adverse events such as Stevens-Johnson syndrome/toxic epidermal necrolysis, which can be life-threatening
As we see this increase in the use of checkpoint inhibitors, the toxicities that can occur from them are becoming more and more obvious for us as dermatologists who have to understand how to treat these patients, Chen said.
Chen said more research and a better understanding is needed to identify the dermatology adverse events caused by checkpoint inhibitors. It will be important, he said, for dermatologists to work with oncologists to address the toxicities in a way that allows patients to remain on their oncology treatments.
When treating patients with dermatology adverse events from checkpoint inhibitors, Chen said dermatologist should avoid immunosupression and possibly limit the strength of systemic steroids.
Visit link:
Cancer Treatment's Checkpoint Inhibitors Are Causing Skin-Related ... - Managed Healthcare Executive
Cognitive Behavioral Therapy Improves Outcomes in Patients With … – Dermatology Advisor
Cognitive Behavioral Therapy Improves Outcomes in Patients With ... Dermatology Advisor
Read the original:
Cognitive Behavioral Therapy Improves Outcomes in Patients With ... - Dermatology Advisor